International, Multi-Institutional Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma
Anirudh Saraswathula,Mohammed N. Ullah,Jacklyn Liu,Yoko Takahashi,Arushi Mahajan,Simonetta Battocchio,Paolo Bossi,Paolo Castelnuovo,Carla Facco,Marco Ferrari,Dawn Carnell,Martin D. Forster,Alessandro Franchi,Amrita Jay,Davide Lombardi,Valerie J. Lund,Davide Mattavelli,Piero Nicolai,Vittorio Rampinelli,Fausto Sessa,Shirley Y. Su,Mario Turri-Zanoni,Laura Ardighieri,Erin McKean,Matt Lechner,Ehab Hanna,Nyall R. London
DOI: https://doi.org/10.1055/s-0044-1791573
2024-10-04
Journal of Neurological Surgery Part B Skull Base
Abstract:Objectives The aims of this study were to analyze the clinical characteristics of patients with recurrent and metastatic sinonasal undifferentiated carcinoma (SNUC) and evaluate the current treatment strategies to help guide future management. Design This is a retrospective cohort study. Setting The study was conducted at six international tertiary treatment centers. Participants Patients with documented diagnoses of recurrent or metastatic SNUC since 1983 were included in the study. Main Outcome Measures Patient demographics and clinical characteristics were collected. Primary outcome measures included disease-specific survival (DSS), overall survival (OS), and time to recurrence (TTR) following initial treatment. Further univariable and multivariable analyses were performed to assess for prognostic factors. Results A total of 97 patients with a mean (standard deviation [SD]) age of 52.4 (15.6) were identified, 15 of whom presented with metastatic SNUC and 90 of whom developed recurrence. Management in both populations was widely variable. For patients with metastatic disease, the 1-year DSS probability was 33.3% (95% confidence interval [CI], 10.8–100%). For patients with recurrent SNUC, the 1- and 5-year DSS probabilities were 45.7% (95% CI, 31.9–65.6%) and 8.6% (95% CI, 2.9–25.3%), respectively. The median (interquartile range [IQR]) TTR was 8 months (3–18.5 months). Multivariable analyses revealed a significant association between orbital involvement on initial presentation and TTR (hazard ratio [HR] = 3.28; 95% CI, 1.45–7.42; p = 0.004). Conclusions To our knowledge, this is the first study addressing metastatic and recurrent SNUC based on a large patient cohort. Orbital extension of the primary SNUC may predict a higher probability of recurrence following treatment, suggesting the possible utility of a more aggressive treatment in this subgroup of patients. A heterogenous patient population and wide variability in management emphasize the challenges in standardizing care; however, dismal survival rates demonstrate the necessity for further evaluation of current approaches to improve evidence-based recommendations. This study was presented at the North American Skull Base Society Annual meeting on February 18, 2024, in Atlanta, Georgia. * These authors contributed equally to this work. † These authors contributed equally to this work and are co-corresponding authors. Received: 16 June 2024 Accepted: 03 September 2024 Article published online: 03 October 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
surgery,clinical neurology